In the development and manufacture of biologics like monoclonal antibodies, recombinant proteins and vaccines—process-related impurities such as host cell DNA (HCD) and host cell proteins (HCPs) are unavoidable byproducts of the expression system used to…
The life sciences landscape is evolving rapidly.In the next few years, immunology, cell therapy and biosimilars are among the most dynamic sub-sectors shaping the industry.Across global markets, regulatory shifts, technology…
Introduction Antibodies are the workhorses of modern biotechnology.They power diagnostics, enable precise research insights and form the backbone of many therapeutic strategies. At the heart of many successful programs lies custom…
The Human Side of Reliable Science Reliable science is often described like it is a property of reagents, instruments, and protocols. In reality, reliability is also a human outcome. It…
For years, “high-quality reagents” meant something fairly straightforward. High purity.A clean COA.Minimal contaminants. That definition worked, until it didn’t. As diagnostics, biologics, and bioanalytical workflows become more complex, reagent quality…
As biopharmaceutical innovation accelerates, so does the complexity of manufacturing reliable biologics, vaccines, and personalized therapies. In 2026, traditional approaches to bioprocess monitoring are no longer sufficient. Plant-wide visibility, real-time…
At first glance, a diagnostic kit looks simple—sample, reagents, readout. But beneath that simplicity is a layer of high-quality recombinant proteins that make reliability, sensitivity, and specificity possible.Whether it’s ELISA, rapid lateral…
In in-vitro diagnostics (IVD) development, few decisions have as much downstream impact as antibody selection and validation. Yet, early-stage antibody validation is often rushed, minimized, or treated as a checkbox exercise—especially…
Biosimilars represent one of the most transformative innovations in modern biopharmaceuticals — offering pathways to therapeutic access, cost reduction, and competitive markets. Unlike small-molecule generics, however, biosimilars are biologics: large,…
Biotechnology today is no longer driven by discovery alone.It is driven by precision, reproducibility and the ability to translate science into scalable impact. From biosimilar drug development to diagnostics, immunology, and…
2025 has been a pivotal year for biosimilars. New regulatory expectations, stronger analytical frameworks, and a renewed emphasis on lifecycle monitoring have pushed developers closer than ever to one key…
In 2025, the life sciences industry faces a paradox.We have more powerful biological tools than ever before yet the margin for analytical error has never been smaller. Small errors, subtle…
